/CARM

CARM Stock - Carisma Therapeutics, Inc.

Q: What is the analyst price target for CARM?

Analyst price target information is not currently available for CARM.

Q: What is CARM's market cap?

Market capitalization information is not currently available for CARM.

Healthcare|Biotechnology|NASDAQ

$0.05-7.69%

$0.00 (-7.69%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+12400.0%upside

Target: $6.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CARM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.69

52W High$1.27

52W Low$0.03

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$19.63M	$14.92M	$9.83M	$26.54M	$11.24M
Gross Profit	$-40,041,000	$-59,206,000	$9.83M	$26.46M	$11.24M
Gross Margin	-204.0%	-396.8%	100.0%	99.7%	100.0%
Operating Income	$-62,179,000	$-88,731,000	$-56,162,000	$-28,161,000	$-28,378,000
Net Income	$-60,477,000	$-86,879,000	$-61,226,000	$-336,000	$-28,349,000
Net Margin	-308.1%	-582.3%	-622.6%	-1.3%	-252.3%
EPS	$-1.46	$-2.59	$-1.52	$-1.01	$-0.70

Company Overview

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

71%

Hold / Neutral

29%

Sell / Underperform

Analyst Consensus🟢 Bullish

5 Bullish2 Neutral/Bearish

Price Targets

Average Target

↑ 16566.7% Upside

Now

Low

Average

$12

High

Based on 7 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 12th 2024	Robert W. Baird	Downgrade	Neutral	$1← $10
December 10th 2024	BTIG Research	Downgrade	Neutral	-
April 11th 2024	BTIG Research	Initiation	Buy	$6
October 3rd 2023	CapitalOne	Initiation	Overweight	$10
July 6th 2023	Evercore ISI	Initiation	Outperform	$12
May 31st 2023	Jefferies	Upgrade	Buy	$7← $0.6
May 24th 2023	H.C. Wainwright	Initiation	Buy	$10
April 14th 2023	Robert W. Baird	Initiation	Outperform	$10

Earnings History & Surprises

CARM

Beat Rate

50%

Last 18 quarters

Avg Surprise

+13.6%

EPS vs Estimate

Beats / Misses

9/7

2 met exactly

Latest EPS

$1.07

Q4 2025

EPS Surprise History

Q1 24

+5.5%

$-0.52vs$-0.55

Q2 24

-24.3%

$-0.46vs$-0.37

Q3 24

+25.0%

$-0.27vs$-0.36

Q4 24

0.0%

$-0.31vs$-0.31

Q1 25

-162.5%

$-0.42vs$-0.16

Q2 25

-83.3%

$-0.22vs$-0.12

Q3 25

0.0%

$-0.12vs$-0.12

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 30, 2026	—	—	—	—
Q4 2025	Nov 12, 2025	—	$1.07	—	—
Q3 2025	Aug 7, 2025	$-0.12	$-0.12	0.0%	= MET
Q2 2025	May 13, 2025	$-0.12	$-0.22	-83.3%	✗ MISS
Q1 2025	Mar 31, 2025	$-0.16	$-0.42	-162.5%	✗ MISS
Q4 2024	Nov 7, 2024	$-0.31	$-0.31	0.0%	= MET
Q3 2024	Aug 8, 2024	$-0.36	$-0.27	+25.0%	✓ BEAT
Q2 2024	May 9, 2024	$-0.37	$-0.46	-24.3%	✗ MISS
Q1 2024	Mar 26, 2024	$-0.55	$-0.52	+5.5%	✓ BEAT
Q4 2023	Nov 9, 2023	$-0.60	$-0.53	+11.7%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.66	$-0.49	+25.8%	✓ BEAT
Q2 2023	May 11, 2023	$-0.89	$-1.93	-116.9%	✗ MISS
Q1 2023	Feb 28, 2023	$-2.20	$-0.80	+63.6%	✓ BEAT
Q4 2022	Nov 7, 2022	$-3.10	$2.00	+164.5%	✓ BEAT
Q3 2022	Aug 8, 2022	$-2.60	$-3.20	-23.1%	✗ MISS
Q2 2022	May 9, 2022	$-2.00	$-0.32	+83.8%	✓ BEAT
Q1 2022	Feb 28, 2022	$-1.47	$0.80	+154.4%	✓ BEAT
Q4 2021	Nov 8, 2021	$-1.40	$7.20	+614.3%	✓ BEAT
Q3 2021	Aug 9, 2021	$-1.27	$-3.00	-136.2%	✗ MISS
Q2 2021	May 10, 2021	$-1.53	$-7.00	-357.5%	✗ MISS

Frequently Asked Questions about CARM

What is CARM's current stock price?

Carisma Therapeutics, Inc. (CARM) is currently trading at $0.05 per share. The stock has moved -7.69% today.

What is the analyst price target for CARM?

The average analyst price target for CARM is $6.00, based on 1 analyst.

What sector is Carisma Therapeutics, Inc. in?

Carisma Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CARM's market cap?

Carisma Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does CARM pay dividends?

No, Carisma Therapeutics, Inc. does not currently pay a dividend to shareholders.